Bioatla investor relations
WebAug 9, 2024 · Forward-looking statements contained in this press release are made as of this date, and BioAtla undertakes no duty to update such information except as required … WebNov 4, 2024 · November 04, 2024 — 12:15 pm EDT. BioAtla, Inc. (BCAB) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to loss of $0.68 ...
Bioatla investor relations
Did you know?
WebMar 23, 2024 · Access Bioatla Inc (BCAB) Investor Relations material, such as Live Earnings Calls, Transcripts, Slides, Reports, and Estimates using Quartr WebAug 17, 2024 · BioAtla is not a large company by global standards. It has a market capitalization of US$445m, which means it wouldn't have the attention of many institutional investors.
WebEdit. BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs. WebNov 17, 2024 · Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. It looks like hedge funds own 12% of BioAtla shares.
WebMay 4, 2024 · First Quarter Financial Results. Cash and cash equivalents as of March 31, 2024 were $219.4 million, compared to $245.0 million as of December 31, 2024. We … WebMar 25, 2024 · Net loss for the full year ended December 31, 2024 was $35.9 million compared to a net loss of $29.8 million for the year 2024. About BioAtla, Inc. BioAtla is a global clinical-stage biotechnology ...
WebThe Investor Relations website contains information about BioAtla, Inc's business for stockholders, potential investors, and financial analysts.
WebJan 10, 2024 · The Investor Relations website contains information about BioAtla, Inc's business for stockholders, potential investors, and financial analysts. chunky boys clothingWebMar 24, 2024 · BioAtla, Inc. (NASDAQ:NASDAQ:BCAB) Q4 2024 Earnings Call Transcript March 23, 2024 4:30 PM ETCompany ParticipantsBruce Mackle - Investor Relations, … chunky braided sweater wool rugWebDec 9, 2024 · BioAtla has initiated Phase 2 trials for its two latest stage antibody-drug conjugate candidates BA3011 and BA3021 in multiple cancer indications, with interim … detergent factories in egyptWebMay 4, 2024 · First Quarter Financial Results. Cash and cash equivalents as of March 31, 2024 were $219.4 million, compared to $245.0 million as of December 31, 2024. We expect current cash and cash equivalents ... chunky braided rugWebBioAtla is a San Diego biotech company that develops novel monoclonal antibody and cell-based therapeutics using our proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody ... 484 … chunky bread shaver lakeWebBioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based … chunky braided sandalsWebNov 3, 2024 · Net loss for the quarter ended September 30, 2024 was $25.8 million compared to a net loss of $22.9 million for the same quarter in 2024. Net cash used in operating activities for the nine months ended September 30, 2024 was $66.1 million compared to net cash used in operating activities of $41.3 million for the same period in … chunky braid stitch